2-chloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carbonitrile | 344561-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carbonitrile
• 英文别名: 2-chloro-7,7-dimethyl-5-oxo-6,8-dihydroquinoline-3-carbonitrile
• CAS: 344561-76-8
• 化学式: C₁₂H₁₁ClN₂O
• 分子量: 234.685
• InChiKey: DGCSTDLEDZVMAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  53.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carbonitrile 、 2-氨基茚 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以53%的产率得到2-(Indan-2-ylamino)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinoline-3-carbonitrile
  参考文献：
  名称：

  Positive and Negative Modulation of Group I Metabotropic Glutamate Receptors

  摘要：

  A discriminating pharmacophore model for noncompetitive metabotropic glutamate receptor antagonists of subtype 1 (mGluR1) was developed that facilitated the discovery of moderately active mGluR1 antagonists. One scaffold was selected for the design of several focused libraries where different substitution patterns were introduced. This approach facilitated the discovery of potent mGluR1 antagonists, as well as positive and negative mGluR5 modulators, because both receptor subtypes share similar binding pockets. For mGluR1 antagonists, a homology model of the mGlu1 receptor was established and a putative binding mode within the receptor's transmembrane domain was visualized.

  DOI：

  10.1021/jm0611298
• 作为产物：
  描述：

  7,7-dimethyl-2,5-dioxo-1,2,5,6,7,8-hexahydro-quinoline-3-carbonitrile 在 三氯氧磷 作用下， 反应 5.0h， 以46%的产率得到2-chloro-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-quinoline-3-carbonitrile
  参考文献：
  名称：

  Positive and Negative Modulation of Group I Metabotropic Glutamate Receptors

  摘要：

  A discriminating pharmacophore model for noncompetitive metabotropic glutamate receptor antagonists of subtype 1 (mGluR1) was developed that facilitated the discovery of moderately active mGluR1 antagonists. One scaffold was selected for the design of several focused libraries where different substitution patterns were introduced. This approach facilitated the discovery of potent mGluR1 antagonists, as well as positive and negative mGluR5 modulators, because both receptor subtypes share similar binding pockets. For mGluR1 antagonists, a homology model of the mGlu1 receptor was established and a putative binding mode within the receptor's transmembrane domain was visualized.

  DOI：

  10.1021/jm0611298

文献信息

• Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
  申请人：Jirgensons Aigars

  公开号：US20050197361A1

  公开（公告）日：2005-09-08

  The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutially acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  该发明涉及四氢喹诺酮衍生物及其药用可接受的盐。该发明还涉及一种制备这种化合物的方法。该发明的化合物是I组mGluR拮抗剂，因此对于控制和预防急性和/或慢性神经系统疾病非常有用。
• GUDRINIETSE, EH. YU.;PAXUROVA, T. F., XIM. TEXNOL. BIOL. AKTIV. SOEDIN., 1974-1983, RIGA, 1983, 18-26
  作者：GUDRINIETSE, EH. YU.、PAXUROVA, T. F.

  DOI：——

  日期：——
• TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP1723116A2

  公开（公告）日：2006-11-22
• US7598384B2
  申请人：——

  公开号：US7598384B2

  公开（公告）日：2009-10-06
• [EN] TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] TETRAHYDROQUINOLINONES ET LEUR UTILISATION COMME ANTAGONISTES DES RECEPTEURS DE GLUTAMATE METABOTROPIQUE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2005082856A2

  公开（公告）日：2005-09-09

  The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.